247 related articles for article (PubMed ID: 31479233)
1. Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington's Disease.
Cong W; Bai R; Li YF; Wang L; Chen C
ACS Appl Mater Interfaces; 2019 Sep; 11(38):34725-34735. PubMed ID: 31479233
[TBL] [Abstract][Full Text] [Related]
2. The neuroprotective transcription factor ATF5 is decreased and sequestered into polyglutamine inclusions in Huntington's disease.
Hernández IH; Torres-Peraza J; Santos-Galindo M; Ramos-Morón E; Fernández-Fernández MR; Pérez-Álvarez MJ; Miranda-Vizuete A; Lucas JJ
Acta Neuropathol; 2017 Dec; 134(6):839-850. PubMed ID: 28861715
[TBL] [Abstract][Full Text] [Related]
3. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
4. mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease.
Ast A; Buntru A; Schindler F; Hasenkopf R; Schulz A; Brusendorf L; Klockmeier K; Grelle G; McMahon B; Niederlechner H; Jansen I; Diez L; Edel J; Boeddrich A; Franklin SA; Baldo B; Schnoegl S; Kunz S; Purfürst B; Gaertner A; Kampinga HH; Morton AJ; Petersén Å; Kirstein J; Bates GP; Wanker EE
Mol Cell; 2018 Sep; 71(5):675-688.e6. PubMed ID: 30193095
[TBL] [Abstract][Full Text] [Related]
5. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
[TBL] [Abstract][Full Text] [Related]
6. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
[TBL] [Abstract][Full Text] [Related]
7. TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models.
Hegde RN; Chiki A; Petricca L; Martufi P; Arbez N; Mouchiroud L; Auwerx J; Landles C; Bates GP; Singh-Bains MK; Dragunow M; Curtis MA; Faull RL; Ross CA; Caricasole A; Lashuel HA
EMBO J; 2020 Sep; 39(17):e104671. PubMed ID: 32757223
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress is increased in C. elegans models of Huntington's disease but does not contribute to polyglutamine toxicity phenotypes.
Machiela E; Dues DJ; Senchuk MM; Van Raamsdonk JM
Neurobiol Dis; 2016 Dec; 96():1-11. PubMed ID: 27544481
[TBL] [Abstract][Full Text] [Related]
9. Rutin protects Huntington's disease through the insulin/IGF1 (IIS) signaling pathway and autophagy activity: Study in Caenorhabditis elegans model.
Cordeiro LM; Machado ML; da Silva AF; Obetine Baptista FB; da Silveira TL; Soares FAA; Arantes LP
Food Chem Toxicol; 2020 Jul; 141():111323. PubMed ID: 32278002
[TBL] [Abstract][Full Text] [Related]
10. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
[TBL] [Abstract][Full Text] [Related]
11. The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington's disease.
Farina F; Lambert E; Commeau L; Lejeune FX; Roudier N; Fonte C; Parker JA; Boddaert J; Verny M; Baulieu EE; Neri C
Sci Rep; 2017 Jun; 7(1):4014. PubMed ID: 28638078
[TBL] [Abstract][Full Text] [Related]
12. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
13. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
Bates EA; Victor M; Jones AK; Shi Y; Hart AC
J Neurosci; 2006 Mar; 26(10):2830-8. PubMed ID: 16525063
[TBL] [Abstract][Full Text] [Related]
14. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics of Huntington's Disease.
Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.
Liu SY; Yu XL; Zhu J; Liu XM; Zhang Y; Dong QX; Ma S; Liu RT
Brain Res; 2018 Oct; 1697():21-33. PubMed ID: 29902468
[TBL] [Abstract][Full Text] [Related]
17. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
18. Nonmammalian Models of Huntington's Disease.
Chongtham A; Barbaro B; Filip T; Syed A; Huang W; Smith MR; Marsh JL
Methods Mol Biol; 2018; 1780():75-96. PubMed ID: 29856015
[TBL] [Abstract][Full Text] [Related]
19. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
Chang R; Liu X; Li S; Li XJ
Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
[TBL] [Abstract][Full Text] [Related]
20. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
